CVE-2020-27266

lowpriority · track · 26EPSS 0.006 · 47 %ileEUUS
grimoire priorityP3 · Track
Exploitable?
—
no known exploitation
Likely / severe?
0.59% (47th) EPSS
CVSS 3.3 · low
Is it mine?
10 products
Check your exposure
Who says so?
4 sources
cnnvd · enisa_euvd · cisa_csaf_ot · nvd

EPSS · scored 2026-10-24

In SOOIL Developments Co., Ltd Diabecare RS, AnyDana-i and AnyDana-A, a client-side control vulnerability in the insulin pump and its AnyDana-i and AnyDana-A mobile applications allows physically proximate attackers to bypass user authentication checks via Bluetooth Low Energy.

01

remediations

Vendor fix, mitigation, or workaround guidance, as published by each source.

A vendor fix is available.

  • FixedAnyDana-Acisa_csaf_ot

    Dana Diabecare recommends users update the Dana Diabecare insulin pumps to Version 3.0 or higher, or to the latest available release. Additionally, users are encouraged to immediately update AnyDana-A and AnyDana-i to Version 3.0 or higher. Also, SOOIL recommends users to apply these mitigating strategies:

  • FixedAnyDana-icisa_csaf_ot

    Dana Diabecare recommends users update the Dana Diabecare insulin pumps to Version 3.0 or higher, or to the latest available release. Additionally, users are encouraged to immediately update AnyDana-A and AnyDana-i to Version 3.0 or higher. Also, SOOIL recommends users to apply these mitigating strategies:

  • FixedDana Diabecare RScisa_csaf_ot

    Dana Diabecare recommends users update the Dana Diabecare insulin pumps to Version 3.0 or higher, or to the latest available release. Additionally, users are encouraged to immediately update AnyDana-A and AnyDana-i to Version 3.0 or higher. Also, SOOIL recommends users to apply these mitigating strategies:

02

cvss

Technical severity, 0–10. One row per scoring source.

6.5
010

base score 0–10 · higher = more severe · hover a vector to decode⚠ sources disagree · low–medium · 3.3–6.5

v2.03.3lowAV:A/AC:L/Au:N/C:P/I:N/A:Nprimary · NVD / NIST USexploitability 6.5 · impact 2.9
v3.16.5mediumCVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:Nprimary · NVD / NIST USexploitability 2.8 · impact 3.6
v3.06.5mediumCVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:Nsecondary · CISA US
v3.16mediumCVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N/E:Usecondary · CVSS-BT (t0sche)
03

weaknesses

The CWE weakness classes this flaw belongs to.

04

affected products (10)

Products and version ranges known to be affected.

05

advisories (1)

Vendor and ecosystem advisories describing this.

  • ICSMA-21-012-01SOOIL Dana Diabecare RS Products2021-01-12icsa · cisa_csaf_otUS

    Successful exploitation of these vulnerabilities could allow an attacker to access sensitive information, modify therapy settings, bypass authentication, or crash the device being accessed. These vulnerabilities could affect patient safety.

06

also known as (3)

Other names and identifiers for this entity.

07

sources

Which sources assert this record, and when.

published 2021-01-19modified 2026-06-17
09

references (5)

External citations — patches, advisories, analysis.

scry

Attackers weaponise vulnerabilities like this against internet-exposed services. See what is exposed on your perimeter with a free passive scan.

Free scan